Peggy Sotiropoulou, Ph.D. – Celyad Oncology discusses Celyad Oncology Announces FDA Clearance of IND Application for CYAD-211, First shRNA-based, Non-Gene Edited Allogeneic CAR T Therapy
Celyad Oncology discusses Celyad Oncology Announces FDA Clearance of IND Application for CYAD-211, First shRNA-based, Non-Gene Edited Allogeneic CAR T Therapy – Inside the study – Peggy S…
